The wearable defibrillator developer revealed GV is an existing investor as it raised more than $145m that will support the launch of its lead product.

Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Existing investors Novartis Venture Fund and Partners Innovation Fund chipped in as the hearing loss therapy developer closed its latest round.

Eli Lilly and WuXi AppTec contributed to what was reportedly a down round for T-cell oncology treatment developer Immunocore following a $320m raise in 2015.

Eli Lilly and WuXi AppTec contributed to what was reportedly a down round for T-cell oncology treatment developer Immunocore following a $320m raise in 2015.

The immuno-oncology therapy developer has raised a sliver over $100m, Takeda Ventures leading a round that included M Ventures, Ipsen Ventures and MRL Ventures Fund.

Tencent took part in a series G led by Andreessen Horowitz that reportedly valued the immersive gaming platform developer at $4bn.

The no-code app development platform has raised a further $51m in a second tranche led by CapitalG, the corporate that also backed its first close in October.

GV and Intel Capital returned to reinvest in the computing technology provider, which was co-founded by Stanford professors and has now raised more than $450m altogether.

The autonomous driving system developer is now valued at over $3bn, having secured $462m including $400m from strategic partner Toyota.